BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 2142807)

  • 1. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
    Campo B; Torelli T; Leidi GL; Corrada P; Bacchioni AM; Ordesi G; Zanitzer L
    Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):237-42. PubMed ID: 2142807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
    Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
    Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
    Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
    Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant chemotherapy using cisplatin (CDDP) and methotrexate (MTX) in carcinoma of the bladder].
    Rocco F; Scardino E; Strada G; Franchini V; Larcher P; Favini P; Baccalin A; Giuberti A; Criscpino S; Tancini G
    Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):249-55. PubMed ID: 2142809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neoadjuvant chemotherapy of locally advanced tumors of the bladder: preliminary experience].
    Ruoppolo M; Bellorofonte C; Gritti A; Gozo M; Ferri PM; Tura M; Zaatar C; Tiraboschi B; Morosini D; Dell'Acqua S
    Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):243-8. PubMed ID: 2142808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
    Voce S; Montanari F; Arnone S; Dal Pozzo C; Suprani G; Cerullo G; Fornarola V
    Arch Esp Urol; 1992 Jun; 45(5):491-8. PubMed ID: 1510485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Conservative treatment of infiltrating cancer of the bladder: neoadjuvant chemotherapy and radiotherapy].
    Prié L; Gaston R; Ferrière JM; Richaud P; Bui BN; Guillou ML
    Cancer Radiother; 1998 Apr; 2 Suppl 1():62s-66s. PubMed ID: 9749081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
    Hoch V; Noll F; Schreiter F
    Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant systemic chemotherapy with VMC (vinblastine, methotrexate and cisplatin) in locally advanced carcinoma of the bladder].
    Maffezzini M; Rigatti P
    Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):219-21. PubMed ID: 2142804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.